Compare Lamb Weston Holdings Inc (LW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Lamb Weston Holdings Inc trades at $53.22 (market cap $7.31B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Lamb Weston Holdings Inc and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Lamb Weston Holdings Inc pays a 2.87% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LW | SYRE | |
|---|---|---|
Market Cap | $7.31B | $7.35B |
Volume | 3,751,735 | 1,624,631 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $108.92 |
52-Week Low | $38.48 | $22.18 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $11.10B | $6.35B |
Dividend Yield | 2.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $51.96, up 3.55% today, showing strong momentum with four consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward trends, though RSI levels suggest potential overbought conditions. Fundamentally, the company maintains solid profitability with 14.17% ROE and 3.85% net margin, while trading at reasonable valuations of 28.39 P/E and 1.09 P/S ratios. Recent dividend payments of $0.38 demonstrate shareholder returns.
LW presents a balanced investment case with analyst consensus at $53.71 offering modest upside. The company's consistent earnings outperformance and cost-saving initiatives provide support, but declining profit margins from 18.85% in 2023 to 3.84% projected for 2026 represent significant headwinds. High debt levels at $3.68 billion and ongoing legal investigations create additional risk factors that warrant careful monitoring.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
